The FDA April 25 approved Exelixis Inc.'s Cabometyx (cabozantinib) for treating patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
RCC is the most common form of kidney cancer in adults, Exelixis said in a press release. Cabometyx, the tablet formulation of cabozantinib, will be available in 20-, 40- or 60-milligram doses. The recommended dose is 60 milligrams orally, once daily, the South San Francisco, Calif.-based company said.
“With today’s announcement, patients with previously treated advanced kidney cancer now have a new option, the first and only approved product demonstrated to help patients live longer while ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.